(Total Views: 481)
Posted On: 02/26/2021 1:54:48 PM
Post# of 72444
From a Redditor, new to r/IPIX posting here with his permission.
Hi, I'm new to reddit but not to IPIX nor drug trials.
IMO The current trial protocol is not going to require Covid-19 patients to choose between SOC and an untested substance. The trials will be with all patients on SOC and some patients receiving SOC plus Brilacidin while the control group receives SOC plus placebo. In Russia the SOC now is either Favipiravir or Remdesivir.. We know Brilacidin+Remdesivir is an extremely potent viricidal combination in vitro. Brilacidin+Favipiravir not so much. We don't know whether the P2 recruitment protocols will bar patients undergoing Favipiravir treatment. We know from the MRSA trials that Brilacidin has a 23 hour half life. We don't know whether IV infusions will deliver enough Brilacidin to Covid 19 infection sites long enough to reduce viral replication to the point of reducing Covid 19 viruses to undetectable levels. If Brilacidin is SARS-2 disruptive to the above extent then even the most modest investor in this stock can expect huge returns, IMO."
Hi, I'm new to reddit but not to IPIX nor drug trials.
IMO The current trial protocol is not going to require Covid-19 patients to choose between SOC and an untested substance. The trials will be with all patients on SOC and some patients receiving SOC plus Brilacidin while the control group receives SOC plus placebo. In Russia the SOC now is either Favipiravir or Remdesivir.. We know Brilacidin+Remdesivir is an extremely potent viricidal combination in vitro. Brilacidin+Favipiravir not so much. We don't know whether the P2 recruitment protocols will bar patients undergoing Favipiravir treatment. We know from the MRSA trials that Brilacidin has a 23 hour half life. We don't know whether IV infusions will deliver enough Brilacidin to Covid 19 infection sites long enough to reduce viral replication to the point of reducing Covid 19 viruses to undetectable levels. If Brilacidin is SARS-2 disruptive to the above extent then even the most modest investor in this stock can expect huge returns, IMO."
(2)
(0)
